ImmuCell Stock

ImmuCell Stock-Based Compensation

The Stock-Based Compensation (SBC) of ImmuCell (ICCC) as of Aug 22, 2026 is 295,871.00 USD. In the previous year, Stock-Based Compensation (SBC) was 326,000.00 USD — a change of -9.24% (lower).

Stock-Based Compensation

295,871.00USD

YoY

-9.24%

Last updated:

Stock-Based Compensation (SBC) of ImmuCell is 2026 295,871.00 USD. Stock-Based Compensation (SBC) of ImmuCell was 2025 326,000.00 USD. It decreases by -9.24% lower compared to the previous year.

The ImmuCell Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
344,016.00 USD
Jan 1, 2019
313,144.00 USD
Jan 1, 2020
253,135.00 USD
Jan 1, 2021
144,313.00 USD
Jan 1, 2022
266,244.00 USD
Jan 1, 2023
368,866.00 USD
Jan 1, 2024
326,000.00 USD
Jan 1, 2025
295,871.00 USD
The ImmuCell Stock-Based Compensation history
YEARStock-Based CompensationYoY
295,871.00USD-9.24%
326,000.00USD-11.62%
368,866.00USD+38.54%
266,244.00USD+84.49%
144,313.00USD-42.99%
253,135.00USD-19.16%
313,144.00USD-8.97%
344,016.00USD+72.19%
199,783.00USD+196.42%
67,399.00USD+190.24%
23,222.00USD-22.60%
30,004.00USD
Access this data via the Eulerpool API

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Stock-Based Compensation (SBC) of ImmuCell is 295,871.00 USD in 2026.

Stock-Based Compensation (SBC) of ImmuCell changed from 326,000.00 USD to 295,871.00 USD, representing a -9.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) ImmuCell since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s ImmuCell historically and in real time.

Access this data via the Eulerpool API

Cash Flow — ImmuCell

All Key Metrics — ImmuCell